By Mrinalika Roy and Sriparna Roy April 20 (Reuters) - The surging popularity of GLP-1 weight-loss drugs is quietly reshaping ...
SARATOGA SPRINGS, NY, UNITED STATES, March 4, 2026 /EINPresswire.com/ -- InteractSafe.com, an independent digital platform helping consumers make safer decisions ...
To learn more about our editorial approach, explore The Direct Message methodology. A class of drugs that millions of people take to manage diabetes and lose weight appears to cut substance use deaths ...
The rise of GLP-1 weight-loss drugs is impacting the U.S. cannabis market as consumer behaviors shift. Cannabis dispensaries are adapting by recommending lower-dose products. Research into GLP-1 drugs ...
Pens for the diabetes drug Ozempic sit on a production line to be packaged at the Danish drugmaker Novo Nordisk's site in Hillerod, Denmark, September 26, 2023. REUTERS/Tom Little March 4 (Reuters) - ...
Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity. GLP-1 receptor ...
Researchers at Washington University School of Medicine in St. Louis show in a new study that GLP-1 medications may be effective at treating and preventing substance use disorders across all major ...
What began as an unexpected observation and “side effect” of some medications converged with decades of addiction neuroscience: GLP-1 receptor agonist medications like Ozempic apparently reduce ...
Add Yahoo as a preferred source to see more of our stories on Google. Pens for the diabetes drug Ozempic sit on a production line to be packaged at the Danish drugmaker Novo Nordisk's site in Hillerod ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results